Pharmaceutical intelligence for Faron Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 21, 2026

Faron Pharmaceuticals Initiates Phase IIb Trial of Bexmarilimab in Higher-risk Myelodysplastic Syndromes

Faron Pharmaceuticals is conducting Phase IIb trial (BEXERA) to evaluate bexmarilimab combined with azacitidine in treatment-naïve higher-risk MDS patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 21, 2026

Faron Pharmaceuticals Initiates Phase IIb Trial of Bexmarilimab in Higher-risk Myelodysplastic Syndromes

Faron Pharmaceuticals is conducting Phase IIb trial (BEXERA) to evaluate bexmarilimab combined with azacitidine in treatment-naïve higher-risk MDS patients.

Competitive activity

No signals indexed for this entity yet.

Assets

bexmarilimab →

Therapeutic areas

Hematology →

Myelodysplastic Syndromes →

Indications

Myelodysplastic Syndromes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.